E-mail Updates
![Key Questions (II). KQ 5: nWhat is the risk of malignancy associated with rhGH use as determined by (a) markers of cancer risk with rhGH (IGF-I increases over 100 ng/ml or IGFBP-3 decreases over 1,000 ng/ml) from studies of rhGH in people with CF [cystic fibrosis], and (b) assessment of evidence on cancer incidence from non-CF patients receiving modest doses of rhGH (0.2 mg/kg per week to 0.6 mg/kg per week) for disorders such as growth hormone deficiency and idiopathic short stature? KQ 6: In patients with CF, how are efficacy, effectiveness, safety, or adverse events impacted by rhGH dose, therapy duration, baseline nutritional status, and concurrent medical therapies? KQ 7: In patients with CF, how do the efficacy, effectiveness, safety, or adverse events of treatment with rhGH differ between subgroups of patients? Subgroup characteristics of interest include, but are not limited to, age (prepubertal, pubertal, postpubertal); gender; baseline clinical status (height, weight, lean body mass, pulmonary function, exercise tolerance, nutritional status); and/or the nature, extent, and effectiveness of prior treatment.](https://webarchive.library.unt.edu/web/20130309181921im_/http://www.effectivehealthcare.ahrq.gov/ehc/images/slideimgs/t021_s031_w160.png)
AHRQ Home |
Contact AHRQ |
Site Map |
Accessibility |
Privacy Policy |
Freedom of Information Act |
Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal
Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364